Literature DB >> 3091459

Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients.

J Schrader, M Kandt, C Zürcher, H Köstering, F Scheler.   

Abstract

Antithrombotic activity, necessary doses and effects on coagulation and lipid variables of the low molecular weight heparin derivative Fragmin were compared to unfractionated (UF) heparin in long-term multicentre trials. Results of more than 10,000 dialyses are reported. On the basis of preliminary studies, UF heparin and Fragmin doses were used that lead to anti-Xa activities of more than 0.5 U/ml. With this dose, sufficient antithrombotic activity was achieved with both heparins. Bleeding complications were not noticed. Partial thromboplastin time (PTT) and thrombin time were only marginally increased by Fragmin (5-8 s) in contrast to UF heparin (PTT 90-120 s, thrombin time 230-260 s). Surprisingly, the elevated levels of factor VIII strongly decreased during the 6-month treatment period with Fragmin and increased again during the following 6-month treatment period with UF heparin. Creatinine, urea, haemoglobin and transaminases did not change in both heparin groups: this excluded reduced dialysis efficiency or occult blood loss. Additionally, 15 patients with acute renal failure and high bleeding risk were dialysed with low doses of Fragmin (anti-FXa: 0.2-0.3 U/ml). No severe bleeding occurred. A continuous ambulant peritoneal dialysis patient with deep vein thrombosis was treated effectively with intraperitoneal application of Fragmin for 6 months without any problems.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091459     DOI: 10.1159/000215357

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

1.  [Low molecular weight heparin: how does it modify lipid metabolism in chronic hemodialysis patients?].

Authors:  H Schneider; Y Schmitt
Journal:  Klin Wochenschr       Date:  1991-10-18

2.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).

Authors:  Steven Soroka; Mohsen Agharazii; Sandra Donnelly; Louise Roy; Norman Muirhead; Serge Cournoyer; Martin MacKinnon; Neesh Pannu; Brendan Barrett; François Madore; Karthik Tennankore; Jo-Anne Wilson; Fiona Hilton; Nancy Sherman; Kevin Wolter; John Orazem; Guillaume Feugère
Journal:  Can J Kidney Health Dis       Date:  2018-11-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.